Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma.

[1]  Shuhua Han,et al.  Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[2]  E. Obi,et al.  Asthma control and disease burden in patients with asthma and allergic comorbidities , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

[3]  M. Sadatsafavi,et al.  Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US , 2018, Cost Effectiveness and Resource Allocation.

[4]  J. Virchow,et al.  Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. , 2017, The journal of allergy and clinical immunology. In practice.

[5]  E. Bleecker,et al.  Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics , 2017 .

[6]  H. Smits,et al.  The effect of tiotropium in combination with olodaterol on house dust mite-induced allergic airway disease. , 2017, Pulmonary pharmacology & therapeutics.

[7]  D. Halpin,et al.  Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. , 2017, Respiratory medicine.

[8]  M. Cazzola,et al.  Role of muscarinic antagonists in asthma therapy , 2017, Expert review of respiratory medicine.

[9]  K. Samitas,et al.  T2-low asthma: current approach to diagnosis and therapy , 2017, Current opinion in pulmonary medicine.

[10]  G. D'Amato,et al.  Anticholinergic drugs in asthma therapy , 2017, Current opinion in pulmonary medicine.

[11]  Kenta Akitsu,et al.  Effects of the addition of tiotropium on airway dimensions in symptomatic asthma. , 2016, Allergy and asthma proceedings.

[12]  W. Busse,et al.  Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. , 2016, Respiratory medicine.

[13]  E. Bleecker,et al.  Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. , 2016, The New England journal of medicine.

[14]  E. Bateman,et al.  Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. , 2016, Respiratory medicine.

[15]  P. O'Byrne,et al.  Tiotropium for the treatment of asthma: a drug safety evaluation , 2016, Expert opinion on drug safety.

[16]  C. Prazma,et al.  Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. , 2016, The New England journal of medicine.

[17]  D. Halpin,et al.  The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial. , 2016, The journal of allergy and clinical immunology. In practice.

[18]  M. Pencina,et al.  Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. , 2015, JAMA.

[19]  E. Pizzichini,et al.  The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD , 2015 .

[20]  Kayleigh Kew,et al.  Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. , 2015, The Cochrane database of systematic reviews.

[21]  E. Bleecker,et al.  Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. , 2015, The Lancet. Respiratory medicine.

[22]  K. Ohta,et al.  Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study , 2015, PloS one.

[23]  R. Gosens,et al.  Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. , 2015, Trends in pharmacological sciences.

[24]  G. Rodrigo,et al.  What is the role of tiotropium in asthma?: a systematic review with meta-analysis. , 2015, Chest.

[25]  D. Price,et al.  Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide , 2015, Journal of asthma and allergy.

[26]  David Price,et al.  Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey , 2014, npj Primary Care Respiratory Medicine.

[27]  Mario Castro,et al.  Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study. , 2014, The Lancet. Respiratory medicine.

[28]  F. Ducharme,et al.  Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. , 2014, The Cochrane database of systematic reviews.

[29]  E. R. Sutherland,et al.  Predictors of response to tiotropium versus salmeterol in asthmatic adults. , 2013, The Journal of allergy and clinical immunology.

[30]  Michael Engel,et al.  Tiotropium in asthma poorly controlled with standard combination therapy. , 2012, The New England journal of medicine.

[31]  Tiotropium for asthma--promise and caution. , 2012, The New England journal of medicine.

[32]  P. Demoly,et al.  Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years , 2012, European Respiratory Review.

[33]  E. R. Sutherland,et al.  Impact of race on asthma treatment failures in the asthma clinical research network. , 2011, American journal of respiratory and critical care medicine.

[34]  J. Eicher,et al.  Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders , 2011, Medical devices.

[35]  E. Bateman,et al.  Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. , 2011, The Journal of allergy and clinical immunology.

[36]  E. R. Sutherland,et al.  Tiotropium bromide step-up therapy for adults with uncontrolled asthma. , 2010, The New England journal of medicine.

[37]  T. Lasserson,et al.  Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. , 2010, The Cochrane database of systematic reviews.

[38]  T. Lasserson,et al.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. , 2010, The Cochrane database of systematic reviews.

[39]  P. Barnes,et al.  Inhaled Corticosteroids , 2010, Pharmaceuticals.

[40]  E. Bateman,et al.  Alternative mechanisms for tiotropium. , 2009, Pulmonary pharmacology & therapeutics.

[41]  L. Heaney,et al.  The prevalence of nonadherence in difficult asthma. , 2009, American journal of respiratory and critical care medicine.

[42]  P. Casarosa,et al.  Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs , 2009, Journal of Pharmacology and Experimental Therapeutics.

[43]  J. Ship,et al.  Dry mouth and its effects on the oral health of elderly people. , 2007, Journal of the American Dental Association.

[44]  T. Lasserson,et al.  Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. , 2007, The Cochrane database of systematic reviews.

[45]  Ruben D. Restrepo,et al.  Use of inhaled anticholinergic agents in obstructive airway disease. , 2007, Respiratory care.

[46]  P. Gibson,et al.  Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. , 2007, The Journal of allergy and clinical immunology.

[47]  B. Lipworth,et al.  Arginine-16 β2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol , 2006, Thorax.

[48]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[49]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[50]  Nicholas J Gross,et al.  Tiotropium Bromide , 2012 .

[51]  A. Herxheimer,et al.  Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. , 2001, BMJ : British Medical Journal.

[52]  B. Lipworth.  Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. , 1999, Archives of internal medicine.

[53]  T L Petty,et al.  Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. , 1998, The Journal of allergy and clinical immunology.

[54]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[55]  J. V. van Noord,et al.  Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. , 1996, The European respiratory journal.